Sepsis News and Research

Latest Sepsis News and Research

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today that the Company has initiated a 200-patient Phase 2 pilot study to examine the efficacy and safety of InflammaGen Shok-Pak as a potential treatment for critically ill patients in the Intensive Care Unit.

12 Mar 2012

InflammaGen to initiate Phase 2 study of new drug/delivery platform for shock

A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego Bioengineering Professor Geert Schmid-Sch-nbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications, and new-onset gastrointestinal bleeding.

12 Mar 2012

Doctors identify promising new treatment for hypophosphatasia

Doctors at Washington University School of Medicine in St. Louis, working with Shriners Hospital for Children and other institutions, have identified a promising new treatment for a rare and sometimes life-threatening bone disorder that can affect infants and young children.

8 Mar 2012

FoxO protein plays a significant role in regulation of skeletal muscle mass

If you want big muscles without working out, there's hope. In the March 2012 print issue of the FASEB Journal, scientists from the University of Florida report that a family of protein transcription factors, called "Forkhead (Fox0)" plays a significant role in the regulation of skeletal muscle mass.

1 Mar 2012

Article in journal Science proposes new look on killer diseases

The immune system protects from infections by detecting and eliminating invading pathogens. These two strategies form the basis of conventional clinical approaches in the fight against infectious diseases.

24 Feb 2012

Natural compound of Chilean avocado plant can combat resistant yellow staphylococci

Aggressive infections in hospitals are an increasing health problem worldwide. The development of bacterial resistance is alarming. Now a young Danish scientist has found a natural substance in a Chilean rainforest plant that effectively supports the effect of traditional treatment with antibiotics.

20 Feb 2012

External cooling to achieve normothermia in patients with septic shock found safe

Fever control using external cooling in sedated patients with septic shock is safe and decreases vasopressor requirements and early mortality, according to a new study from researchers in France.

18 Feb 2012

Induction of labor does not minimize risk of respiratory problems, infection in infants

In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in Dallas, Texas, researchers will report findings that suggest that induction of labor in patients who suffer a rupture of membranes between the 34th and 37th week of gestation (before the onset of labor) does not reduce the risk of infection or respiratory problems in the newborn.

10 Feb 2012

Adaptive radiotherapy may benefit patients with head and neck cancer

Researchers led by a senior investigator at Hofstra-North Shore LIJ School of Medicine and The Feinstein Institute for Medical Research have released initial findings from a first-of-a-kind clinical trial in adaptive radiotherapy (ART) for head and neck cancer.

10 Feb 2012

Researchers examine effectiveness of Omega 3 in treating psychiatric symptoms

Researchers at Zucker Hillside Hospital's Recognition and Prevention (RAP) Program who have worked with teenagers at risk for serious mental illness for the past decade are now studying the effectiveness of Omega 3 fatty acids (fish oil) for treating psychiatric symptoms.

9 Feb 2012

Routine 4CMenB immunizations effective against meningococcal strains in infants

Administration of routine infant immunizations with a vaccine for serogroup B Neisseria meningitidis, a bacterium that is a cause of serious disease such as sepsis and meningitis, was effective against meningococcal strains and produced minimal interference with the response to the routine vaccinations, according to a study in the February 8 issue of JAMA.

8 Feb 2012

Merck receives FDA approval for JANUMET XR to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration approved JANUMET XR (sitagliptin and metformin hydrochloride extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA (sitagliptin), with extended-release metformin.

3 Feb 2012

Interim results from Allos Therapeutics' FOLOTYN and bexarotene Phase 1 combination study on CTCL

Allos Therapeutics, Inc. today reported interim results from the Company's ongoing Phase 1 combination study of FOLOTYN and bexarotene in patients with relapsed or refractory cutaneous T-cell lymphoma.

31 Jan 2012

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

30 Jan 2012

IGC researcher awarded ERC Advanced Grant for tissue damage study

There is more to fighting infection than just clearing the body of pathogens. As important as resisting infection, is limiting damage to the host's tissue caused, very frequently, by toxins produced by pathogens or by components of the host immune response that clears those pathogens.

30 Jan 2012

New study aims to prevent bacterial infections in sub-Saharan African kids

Bacteria infections - most of which are preventable via vaccines readily available in the developed world - and not malaria are the leading cause of death for children in sub-Saharan Africa. A new Michigan State University project based in Nigeria and funded by a $5.8 million grant aims to help prevent these diseases by collecting local data on the ailments, spurring vaccine use and development. Funded by the Bill & Melinda Gates Foundation, the research led by Stephen Obaro focuses on diseases such as pneumonia, sepsis and meningitis.

25 Jan 2012

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.

From Baxter International Inc. 24 Jan 2012

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012

Awake ECMO may be an effective bridging strategy for lung transplantation candidates

Extracorporeal membrane oxygenation (ECMO) support in awake, non-intubated patients may be an effective strategy for bridging patients to lung transplantation, according to a new study from Germany.

21 Jan 2012

InflaRx completes IFX-1 phase I study on acute inflammatory diseases

InflaRx announced today the successful completion of its recent clinical phase I study investigating its lead drug candidate IFX-1, a new first in class monoclonal antibody inhibiting complement driven inflammation. The trial reached its anticipated endpoints, demonstrating that IFX-1 is safe and well tolerated while displaying desirable PK and PD parameters.

18 Jan 2012